+

ZA200706740B - Quinazolinone T-type calcium channel antagonists - Google Patents

Quinazolinone T-type calcium channel antagonists

Info

Publication number
ZA200706740B
ZA200706740B ZA200706740A ZA200706740A ZA200706740B ZA 200706740 B ZA200706740 B ZA 200706740B ZA 200706740 A ZA200706740 A ZA 200706740A ZA 200706740 A ZA200706740 A ZA 200706740A ZA 200706740 B ZA200706740 B ZA 200706740B
Authority
ZA
South Africa
Prior art keywords
type calcium
quinazolinone
calcium channel
channel antagonists
compounds
Prior art date
Application number
ZA200706740A
Other languages
English (en)
Inventor
James C Barrow
Rowena V Cube
Ngo Phung Le
Kenneth E Rittle
Yang Zhiqiang
Steven D Young
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of ZA200706740B publication Critical patent/ZA200706740B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/78Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80Oxygen atoms
    • C07D239/82Oxygen atoms with an aryl radical attached in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/78Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA200706740A 2005-03-09 2007-08-14 Quinazolinone T-type calcium channel antagonists ZA200706740B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65995405P 2005-03-09 2005-03-09

Publications (1)

Publication Number Publication Date
ZA200706740B true ZA200706740B (en) 2008-09-25

Family

ID=36992208

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200706740A ZA200706740B (en) 2005-03-09 2007-08-14 Quinazolinone T-type calcium channel antagonists

Country Status (15)

Country Link
US (2) US7745452B2 (xx)
EP (1) EP1858520B1 (xx)
JP (1) JP2008533020A (xx)
KR (1) KR20070110081A (xx)
CN (1) CN101137380A (xx)
AT (1) ATE527243T1 (xx)
AU (1) AU2006223469A1 (xx)
BR (1) BRPI0608343A2 (xx)
CA (1) CA2600868A1 (xx)
IL (1) IL185391A0 (xx)
MX (1) MX2007010965A (xx)
NO (1) NO20075074L (xx)
RU (1) RU2007137266A (xx)
WO (1) WO2006098969A2 (xx)
ZA (1) ZA200706740B (xx)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7745452B2 (en) * 2005-03-09 2010-06-29 Merck Sharp & Dohme Corp. Quinazolinone T-type calcium channel antagonists
CA2685753A1 (en) 2007-05-09 2008-11-20 Neuromed Pharmaceuticals Ltd. Bicyclic pyrimidine derivatives as calcium channel blockers
CA2692783A1 (en) * 2007-07-10 2009-01-15 Merck Sharp & Dohme Corp. Quinazolinone t-type calcium channel antagonists
US8273749B2 (en) 2007-10-04 2012-09-25 Merck Sharp & Dohme Corp. N-substituted oxindoline derivatives as calcium channel blockers
AU2008308092B2 (en) * 2007-10-05 2013-07-11 Msd K.K. Benzoxazinone derivative
WO2010047674A1 (en) 2008-10-20 2010-04-29 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Low molecular weight thyroid stimulating hormone receptor (tshr) agonists
FR2937552B1 (fr) * 2008-10-27 2011-05-06 Biocodex Composition pharmaceutique destinee a la prevention ou au traitement du syndrome de sevrage alcoolique
US9206154B2 (en) 2010-04-08 2015-12-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inverse agonists and neutral antagonists for the TSH receptor
CA2800521A1 (en) 2010-05-24 2011-12-01 Toa Eiyo Ltd. Fused imidazole derivative
WO2014048532A1 (en) * 2012-09-26 2014-04-03 Merck Patent Gmbh Quinazolinone derivatives as parp inhibitors
IN2014CH00304A (xx) * 2014-01-24 2015-09-04 Discovery Intermediates Pvt Ltd
US9145388B2 (en) 2014-02-19 2015-09-29 King Fahd University Of Petroleum And Minerals 6-piperazinyl-3,4-dihydroquinazolin-2(1H)-ones
JP6500201B2 (ja) 2014-05-28 2019-04-17 トーアエイヨー株式会社 置換トロパン誘導体
JP6957460B2 (ja) 2015-10-22 2021-11-02 カビオン・インコーポレイテッドCavion, Inc. アンジェルマン症候群および関連する障害の処置方法
CA3053781A1 (en) 2017-02-15 2018-08-23 Cavion, Inc. Benzopyran and naphalene derivatives and their uses as calium channel inhibitors
CN106749045B (zh) * 2017-03-03 2020-02-14 上海交通大学 一种d-氨基酸氧化酶抑制剂及其制法和应用
US11324733B2 (en) 2017-04-26 2022-05-10 Cavion, Inc. Methods for improving memory and cognition and for treating memory and cognitive disorders
MX2021003706A (es) 2018-10-03 2021-11-04 Cavion Inc Tratamiento del temblor esencial usando (r)-2-(4-isopropilfenil)-n -(1-(5-(2,2,2- trifluoroetoxi)piridin-2-il)etil)acetamida.
BR112022000429A2 (pt) 2019-07-11 2022-03-29 Praxis Prec Medicines Inc Formulações de moduladores do canal de cálcio tipo t e métodos de uso dos mesmos
AR127404A1 (es) 2021-10-20 2024-01-17 Insilico Medicine Ip Ltd Inhibidores de la metionina adenosiltransferasa 2a (mat2a) y usos de los mismos

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL102764A0 (en) * 1991-08-16 1993-01-31 Merck & Co Inc Quinazoline derivatives,and pharmaceutical compositions containing them
WO1993004047A1 (en) * 1991-08-16 1993-03-04 Merck & Co., Inc. Quinazoline derivatives as inhibitors of hiv reverse transcriptase
DE4320347A1 (de) * 1993-06-19 1994-12-22 Boehringer Mannheim Gmbh Quinazolin-Derivate und diese enthaltende Arzneimittel
EP1066039A4 (en) * 1998-03-02 2003-02-26 Cocensys Inc SUBSTITUTED QUINAZOLINE AND THEIR ANALOGS AND USES
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
JP3691341B2 (ja) * 2000-05-16 2005-09-07 日新製鋼株式会社 精密打抜き性に優れたオーステナイト系ステンレス鋼板
AU2003277418A1 (en) * 2002-10-17 2004-05-04 Merck And Co., Inc. Enhancement of sleep with t-type calcium channel antagonists
CN1856310A (zh) * 2003-09-23 2006-11-01 默克公司 喹唑啉钾通道抑制剂
US20070010537A1 (en) * 2004-08-20 2007-01-11 Kazumasa Hamamura Fused pyramidine derivative and use thereof
US7745452B2 (en) * 2005-03-09 2010-06-29 Merck Sharp & Dohme Corp. Quinazolinone T-type calcium channel antagonists
CA2573525A1 (en) * 2006-01-12 2007-07-12 Hitachi, Ltd. Materials location system and selecting method of materials receiving locations

Also Published As

Publication number Publication date
AU2006223469A1 (en) 2006-09-21
CN101137380A (zh) 2008-03-05
WO2006098969A2 (en) 2006-09-21
EP1858520A2 (en) 2007-11-28
US7745452B2 (en) 2010-06-29
IL185391A0 (en) 2008-02-09
US20100261741A1 (en) 2010-10-14
NO20075074L (no) 2007-11-30
US20080167329A1 (en) 2008-07-10
BRPI0608343A2 (pt) 2016-10-04
EP1858520B1 (en) 2011-10-05
CA2600868A1 (en) 2006-09-21
MX2007010965A (es) 2007-09-19
ATE527243T1 (de) 2011-10-15
JP2008533020A (ja) 2008-08-21
EP1858520A4 (en) 2010-02-10
KR20070110081A (ko) 2007-11-15
RU2007137266A (ru) 2009-04-20
WO2006098969A3 (en) 2007-03-01

Similar Documents

Publication Publication Date Title
ZA200706740B (en) Quinazolinone T-type calcium channel antagonists
WO2007120729A3 (en) Pyridyl amide t-type calcium channel antagonists
MX2010004530A (es) Antagonistas de los canales de calcio tipo t de heterociclo fenil amida.
WO2007002884A3 (en) 4-fluoro-piperidine t-type calcium channel antagonists
WO2007002361A3 (en) 3-fluoro-piperidine t-type calcium channel antagonists
TW200714604A (en) Substituted heterocycles and the uses thereof
HK1092467A1 (en) N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n-
TW200716546A (en) Oxindole compounds and their uses as therapeutic agents
TW200738724A (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
MY145077A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2008008551A3 (en) 2-substituted proline bis-amide orexin receptor antagonists
TW200800976A (en) New compounds for the treatment of neurological, psychiatric or pain disorders
TW200724543A (en) Heterocyclic compounds and their uses as therapeutic agents
DE602007008434D1 (de) Rezeptoren
EA201690265A2 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
HK1166983A1 (zh) 包含用於治療疾病或紊亂的化合物的固體形式,其組合物,及其用途
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
TW200716091A (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
WO2007126934A3 (en) Amidoethylthioether orexin receptor antagonists
SG151327A1 (en) Deazapurines useful as inhibitors of janus kinases
DE602004013563D1 (de) Rantagonisten
WO2004087649A3 (en) Benodiazepine spirohydantoin cgrp receptor antagonists
MX2009010127A (es) Compuestos utiles como inhibidores de janus cinasas.
MY149492A (en) Immunoglobulins directed against nogo
WO2006058868A3 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载